Table 1. Patient characteristics.

Characteristic	All patients, N=97 (%)	No irAE, N=48 (%)	Grade 1/2 irAE, N=42 (%)	Grade ≥3 irAE, N=7 (%)	P value
Median age (range)	63.8 (31.1–80.9) years	63.0 (31.1–80.9) years	63.8 (42.0–80.3) years	72.1 (63.1–75.6) years	0.190
Sex					1.000
Male	48 [50]	24 [50]	21 [50]	3 [43]
Female	49 [50]	24 [50]	21 [50]	4 [57]
Histology					0.302
Adenocarcinoma	74 [76]	36 [75]	34 [81]	4 [57]
Squamous cell carcinoma	15 [16]	9 [19]	5 [12]	1 [14]
Large cell, other	8 [8]	3 [6]	3 [7]	2 [29]
EGFR mutation					0.339
Positive	12 [12]	8 [17]	4 [10]	0
Negative	71 [73]	31 [64]	33 [78]	7 [100]
Unknown	14 [15]	9 [19]	5 [12]	0
ALK rearrangement					0.141
Positive	1 [1]	1 [2]	0	0
Negative	79 [82]	35 [73]	37 [88]	7 [100]
Unknown	17 [17]	12 [25]	5 [12]	0
PD-L1 expression					0.372
Positive (any)	35 [36]	13 [27]	18 [43]	4 [57]
Negative	11 [11]	6 [13]	5 [12]	0
Unknown	51 [53]	29 [60]	19 [45]	3 [43]
Smoking status					0.936
Current	11 [11]	6 [13]	4 [10]	1 [14]
Past	62 [64]	29 [60]	28 [67]	5 [72]
Never	24 [25]	13 [27]	10 [23]	1 [14]
Prior lines of therapy					0.103
0	13 [13]	3 [6]	6 [14]	4 [58]
1	25 [26]	14 [29]	10 [24]	1 [14]
2	26 [27]	13 [27]	12 [29]	1 [14]
3 or more	33 [34]	18 [38]	14 [33]	1 [14]
Therapy type					0.49
Anti-PD-1	79 [81]	40 [83]	34 [81]	5 [71]
Anti-PD-L1	16 [17]	6 [13]	8 [19]	2 [29]
Anti-PD-L1 & anti-CTLA-4	2 [2]	2 [4]	0	0

irAE, immune-related adverse event; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; PD-L1, programmed death-ligand 1; CTLA-4, cytotoxic T-lymphocyte associated antigen 4.